Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Stoke Therapeutics, Inc.
- STK-002READOUTCash runway at this date: 5mo
- zorevunersenREADOUTCash runway at this date: 2mo
- Cash runway at this date: -1mo
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Active, not recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
zorevunersen
Dravet Syndrome
NCT06872125Enrollment170StartJun 2025Primary CompletionMar 2027est.READOUTCompletionOct 2028est. - Phase 2Active, not recruiting
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
zorevunersen (STK-001)
Dravet Syndrome
NCT04740476Enrollment60StartJan 2021Primary CompletionMar 2029est.CompletionMar 2029est. - Phase 1/2Completed
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses
Dravet Syndrome
NCT04442295Enrollment62StartJun 2020Primary CompletionNov 2023CompletionNov 2023
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Active, not recruiting | zorevunersen | NCT06872125 |
| Phase 2 | Active, not recruiting | zorevunersen (STK-001) | NCT04740476 |
| Phase 1/2 | Completed | STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses | NCT04442295 |